BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn 2020;20:255-64. [PMID: 31608720 DOI: 10.1080/14737159.2019.1680284] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Garrido Siles M, López-beltran A, Pelechano P, García Vicente AM, Gironés Sarrió R, González-haba Peña E, Rodríguez Antolín A, Zapatero A, Arranz JÁ, Climent MÁ. Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. Cancers 2022;14:3968. [DOI: 10.3390/cancers14163968] [Reference Citation Analysis]
2 Moisoiu T, Dragomir MP, Iancu SD, Schallenberg S, Birolo G, Ferrero G, Burghelea D, Stefancu A, Cozan RG, Licarete E, Allione A, Matullo G, Iacob G, Bálint Z, Badea RI, Naccarati A, Horst D, Pardini B, Leopold N, Elec F. Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer. Mol Med 2022;28:39. [PMID: 35365098 DOI: 10.1186/s10020-022-00462-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
3 Michaeli JC, Michaeli T, Boch T, Albers S, Michaeli DT. Socio-economic burden of disease: survivorship costs for bladder cancer. Journal of Cancer Policy 2022. [DOI: 10.1016/j.jcpo.2022.100326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Aghamir SMK, Gholami K, Le Calvez-kelm F. Liquid biopsy as a new tool for diagnosis, monitoring, and personalized medicine in urogenital cancers. Liquid Biopsy in Urogenital Cancers and its Clinical Utility 2022. [DOI: 10.1016/b978-0-323-99884-0.00009-4] [Reference Citation Analysis]
5 Makarem M, García-Pardo M, Leighl NB. Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers (Basel) 2021;13:5299. [PMID: 34771462 DOI: 10.3390/cancers13215299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lenis AT, Pietzak EJ. Bladder Cancer Genomics: Indications for Sequencing and Diagnostic Implications. Comprehensive Diagnostic Approach to Bladder Cancer 2021. [DOI: 10.1007/978-3-030-82048-0_11] [Reference Citation Analysis]
7 Wang X, Qiu Z, Ji X, Ning W, An Y, Wang S, Zhang H. A novel workflow for cancer blood biomarker identification. Ann Transl Med 2020;8:1430. [PMID: 33313175 DOI: 10.21037/atm-20-2047] [Reference Citation Analysis]
8 Hosen MI, Forey N, Durand G, Voegele C, Bilici S, Avogbe PH, Delhomme TM, Foll M, Manel A, Vian E, Meziani S, De Tilly B, Polo G, Lole O, Francois P, Boureille A, Pisarev E, Salas AROSE, Monteiro-Reis S, Henrique R, Byrnes G, Jeronimo C, Scelo G, McKay JD, Calvez-Kelm FL, Zvereva M. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. Cancers (Basel) 2020;12:E3541. [PMID: 33260905 DOI: 10.3390/cancers12123541] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
9 Kang HW, Kim WJ, Yun SJ. The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. Transl Cancer Res 2020;9:6609-23. [PMID: 35117271 DOI: 10.21037/tcr-20-1243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]